Critical Comparison: Senesco Technologies (SVON) vs. Its Rivals
Senesco Technologies (OTCMKTS: SVON) is one of 95 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Senesco Technologies to related companies based on the strength of its institutional ownership, profitability, valuation, dividends, risk, analyst recommendations and earnings.
This table compares Senesco Technologies and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Senesco Technologies Competitors||-912.91%||-186.15%||-28.31%|
Valuation & Earnings
This table compares Senesco Technologies and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Senesco Technologies||N/A||-$2.26 million||-1.04|
|Senesco Technologies Competitors||$224.58 million||$58.11 million||-1.01|
Senesco Technologies’ competitors have higher revenue and earnings than Senesco Technologies. Senesco Technologies is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This is a summary of current ratings and recommmendations for Senesco Technologies and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Senesco Technologies Competitors||166||554||1216||16||2.55|
As a group, “Biotechnology” companies have a potential upside of 54.39%. Given Senesco Technologies’ competitors higher probable upside, analysts plainly believe Senesco Technologies has less favorable growth aspects than its competitors.
Insider & Institutional Ownership
20.4% of shares of all “Biotechnology” companies are owned by institutional investors. 25.1% of Senesco Technologies shares are owned by insiders. Comparatively, 18.5% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Volatility & Risk
Senesco Technologies has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500. Comparatively, Senesco Technologies’ competitors have a beta of 1.13, suggesting that their average stock price is 13% more volatile than the S&P 500.
Senesco Technologies competitors beat Senesco Technologies on 5 of the 9 factors compared.
About Senesco Technologies
Sevion Therapeutics, Inc. is a development-stage biotech company. The Company is engaged in building and developing a portfolio of therapeutics, from both internal discovery and acquisition, for the treatment of cancer and immunological diseases. The Company is engaged in the development and licensing of technology to discover and engineer monoclonal antibodies. The Company’s product candidates are derived from multiple technology platforms, such as cell-based arrayed antibody discovery, ultralong antibody scaffolds and Chimerasome nanocages. The Company has various antibodies in its preclinical pipeline. The Company’s antibody therapeutic candidates target the potassium channel, voltage dependent (Kv1.3) ion channel, which is essential in the pathogenesis of several autoimmune and inflammatory disorders. Other antibodies in its pipeline target cell surface molecules involved in cancer progression.
Receive News & Stock Ratings for Senesco Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senesco Technologies Inc. and related stocks with our FREE daily email newsletter.